Page 16 - Journal of Special Operations Medicine - Summer 2015

Other important studies to consider would be to com- potentials outcome parameters. Otol Neurotol. 2011;32:
pare cognitive decline experienced with medication to 497–503.
the cognitive decline experienced with motion sickness. 17. Doweck I, Gordon CR, Spitzer O, et al. The vestibulo-ocular
reflex (VOR) under the influence of cinnarizine. J Vestib Res.
It is reasonable to postulate that someone who is inca- 1994;4:215–220.
pacitated from motion sickness will operate better on 18. Nicholson AN, Stone BM, Turner C, et al. Central effects
a medication that relieves the motion sickness, with or of cinnarizine: restricted use in aircrew. Aviat Space Environ
without fatigue, as compared to degraded ability to op- Med. 2002;73:570–574.
erate while incapacitated. 19. Gil A, Nachum Z, Tal D, et al. A Comparison of cinnarizine
and transdermal scopolamine for the prevention of seasick-
ness in naval crew: a double-blind, randomized, crossover
Disclaimer study. Clin Neuropharmacol. 2012;35:37–39.
20. Pingree BJW, Pethybridge RJ. A comparison of the efficacy of
The views expressed herein are those of the authors and cinnarizine with scopolamine in the treatment of seasickness.
Aviat Space Environ Med. 1994;65:597–605.
do not reflect the official policy of the Department of the 21. Gil A, Nachum Z, Dachir S, et al. Scopolamine patch to pre-
Air Force, Department of Defense, or the US Government. vent seasickness: clinical response vs. plasma concentration in
sailors. Aviat Space Environ Med. 2005;76:766–770.
22. Gordon CR, Gonen A, Nachum Z, et al. The effects of di-
Disclosure menhydrinate, cinnarizine and transdermal scopolamine on
The authors of this manuscript have nothing to disclose. performance. J Psychopharmacol. 2001;15:167–172.
23. Estrada A, LeDuc PA, Curry IP, et al. Airsickness prevention
in helicopter passengers. Aviat Space Environ Med. 2007;78:
References 408–413.
24. Hoyt RE, Lawson BD, McGee HA, et al. Modafinil as a po-
1. Jacobs ME, Hawley CG. Safety and survival at sea. In: Auer- tential motion sickness countermeasure. Aviat Space Environ
bach PS, ed. Wilderness medicine. 6th ed. Philadelphia, PA: Med. 2009;80:709–715.
Elsevier; 2012:1667–1668. 25. Kovac AL, Pearman MH, Khalil SN, et al. Ondansetron pre-
2. Shupak A, Gordon CR. Motion sickness: advances in patho- vents postoperative emesis in male outpatients. J Clin Anesth.
genesis, prediction, prevention, and treatment. Aviat Space 1996;8:644–651.
Environ Med. 2006;77:1213–1223. 26. Hershkovitz D, Asna N, Shupak A, et al. Ondansetron for the
3. Golding JF, Gresty MA. Motion sickness. Curr Opin Neurol. prevention of seasickness in susceptible sailors: an evaluation
2005;18:29–34. at sea. Aviat Space Environ Med. 2009;80:643–646.
4. Murdin L, Golding J, Bronstein A. Managing motion sick-
ness. BMJ. 2011;343:d7430.
5. Cuomo-Granston A, Drummond PD. Migraine and motion
sickness: what is the link? Prog Neurobiol. 2010;91:300–312.
6. Eggers SDZ, Neff BA, Shepard NT, et al. Comorbidities in Capt Lyon, USAF, MC, is a flight surgeon/emergency medi-
vestibular migraine. J Vestib Res. 2014;24:387–395. cine physician at Pope Army Airfield, North Carolina. E-mail:
7. Sharon JD, Hullar TE. Motion sensitivity and caloric respon- regan.lyon@gmail.com.
siveness in vestibular migraine and Meniere’s disease. Laryn-
goscope. 2014;124:969–973. Lt Col Rush, USAF, is pararescue medical director, 103rd
8. Brown JH, Taylor P. Muscarinic receptor agonists and an- Rescue Squadron (New York), Departments of Radiation
tagonists. In: Goodman G, Gilman A, Ruddon RW, et al., eds. Oncology and Neurosurgery, New York University Langone
The pharmacological basis of therapeutics. 9th ed. New York, Medical Center, New York, New York.
NY: McGraw-Hill Publishing Company; 1996:141–160.
9. Medina J. 2 Tots, a sailboat and a storm over parenting. The Dr Roland is Mendik Foundation Professor and chair, De-
New York Times. 7 April 2014. http://www.nytimes.com/2014 partment of Otolaryngology-Head and Neck Surgery, profes-
/04/08/us/2-tots-a-sailboat-and-a-storm-over-parenting.html
?_r=2. Accessed 7 April 2014. sor of neurosurgery, New York University Langone Medical
10. Pethybridge RJ. Sea sickness incidence in Royal Navy ships. Center, New York, New York.
Gosport, England: Institute of Naval Medicine; 1982. INM
Report 37/82. Dr Jethanamest is with the Department of Otolaryngology-
11. Rogers D, Syoc D. Motion sickness. Updated April 2010. Air Head and Neck Surgery, New York University Langone Medi-
Force Waiver Guide. Case No.: 88ABW-2013-5432, 20 De- cal Center, New York, New York.
cember 2013.
12. Tal D, Bar R, Nachum Z, et al. Postural dynamics and habit- Capt Schwan, USAF, MC, is a flight surgeon, 1st Special
uation to seasickness. Neuroscience Lett. 2010;479:134–137. Operations Support Squadron, Hurlburt Field, Florida.
13. US Air Force. Official Air Force Aerospace Medicine Ap-
proved Medications. Approved by AF/SG3P on 9 Jan 2014.
14. Shupak A, Doweck I, Gordon CR, et al. Cinnarizine in the Col Kharod, USAF, MC, is senior flight surgeon, Military
prophylaxis of seasickness: laboratory vestibular evaluation EMS and Disaster Medicine Fellow, San Antonio Uniformed
and sea study. Clin Pharmacol Ther. 1994;55:670–680. Services Health Education Consortium, Joint Base San Anto-
15. Emanuel MB. Specific calcium antagonists in the treatment of nio, Fort Sam Houston, Texas.
peripheral vascular disease. Angiology. 1979;30:454–469.
16. Vanspauwen R, Weerts A, Hendrickx M, et al. No effects of
anti-motion sickness drugs on vestibular evoked myo genic

6 Journal of Special Operations Medicine Volume 15, Edition 2/Summer 2015